Commentary
Volume 07:04, 2024

Journal of Clinical Neurology and Neurosurgery

ISSN: 2684-6012 Open Access

Managing Cognitive and Motor Symptoms of Huntington's disease

Wang Cui*

Department of Neurology, The Affiliated Hospital of Chifeng University, Chifeng, China

Introduction

Huntington's Disease (HD) is a progressive neurodegenerative disorder characterized by a triad of symptoms: motor dysfunction, cognitive decline and psychiatric disturbances. Managing these symptoms effectively requires a multifaceted approach tailored to each individual's needs, focusing on both pharmacological and non-pharmacological strategies. Motor symptoms in HD can be particularly challenging, with chorea—uncontrolled, jerky movements—being one of the hallmark features. These movements can lead to difficulties with fine motor skills, balance and overall coordination, complicating daily activities and impacting quality of life. In addition to chorea, patients may experience dystonia, characterized by sustained muscle contractions and bradykinesia, which involves slowness of movement [1].

Description

Pharmacological treatment options for managing motor symptoms often include medications like tetrabenazine and deutetrabenazine. These drugs are designed to reduce chorea by depleting neurotransmitters that contribute to the excessive, involuntary movements. Although effective for some patients, these medications can come with side effects, including depression and sedation. Therefore, careful monitoring and dosage adjustments are essential to balance symptom relief with potential adverse effects. Another class of medications, antipsychotics such as olanzapine and risperidone, can be useful for managing motor symptoms, particularly when chorea is accompanied by psychiatric symptoms. These drugs may help reduce motor agitation and improve overall functioning. However, they must be used cautiously, as they can exacerbate other symptoms or contribute to weight gain and metabolic issues.

Non-pharmacological interventions are also crucial in managing motor symptoms. Occupational therapy and physical therapy can help patients maintain their motor skills and adapt to changes in their physical abilities. Therapists work with individuals to develop strategies for daily tasks, improve balance and enhance overall mobility. These therapies are designed not only to address current difficulties but also to anticipate future challenges and promote long-term function. Speech therapy is another vital component of the non-pharmacological management strategy. As HD progresses, speech and swallowing difficulties often arise. Speech therapists can assist in developing techniques to improve communication and prevent aspiration during eating. These therapies can significantly impact patients' quality of life by ensuring that they can express themselves and maintain adequate nutrition [2,3].

Cognitive symptoms in HD involve a gradual decline in cognitive functions, including attention, executive function, memory and problem-solving abilities. These changes can lead to difficulties in planning, organizing and completing tasks, often resulting in significant challenges in daily living and increased dependency. Pharmacological treatments for cognitive symptoms are less well-defined compared to those for motor symptoms. Cholinesterase inhibitors, commonly used in Alzheimer's disease, have shown some promise in managing cognitive decline in HD. These drugs work by increasing levels of acetylcholine, a neurotransmitter important for memory and learning. However, the efficacy of these medications in HD varies and they may not be suitable for all patients.

Cognitive rehabilitation therapy offers a valuable non-pharmacological approach to managing cognitive symptoms. This type of therapy focuses on improving specific cognitive functions through targeted exercises and strategies. Cognitive rehabilitation can help patients develop coping strategies and adaptive techniques to manage cognitive deficits, enhancing their ability to perform daily activities and maintain independence. In addition to cognitive rehabilitation, supportive care from mental health professionals can play a significant role in addressing cognitive decline. Psychologists or neuropsychologists can conduct comprehensive assessments to identify specific cognitive challenges and provide tailored interventions. They can also support patients and families in understanding and adapting to cognitive changes, offering strategies to manage stress and improve coping mechanisms [4,5].

Psychiatric symptoms, including depression, anxiety and irritability, often accompany HD and can exacerbate both motor and cognitive difficulties. These symptoms can be particularly challenging, as they not only affect the patient's mental well-being but also have a profound impact on their overall functioning and quality of life. Pharmacological treatment for psychiatric symptoms typically involves the use of antidepressants or anxiolytics. Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly prescribed for depression and anxiety, offering benefits with relatively few side effects. However, it is important to monitor patients closely for any potential interactions with other medications used to manage motor symptoms.

Psychiatric support is also crucial in the non-pharmacological management of HD. Psychotherapy, including Cognitive-Behavioral Therapy (CBT), can help patients manage symptoms of depression and anxiety by addressing negative thought patterns and promoting coping strategies. Additionally, support groups can provide valuable social support and a sense of community for both patients and their families. Family and caregiver support is a fundamental aspect of managing HD, as the disease often places a significant burden on loved ones. Providing education about the disease, offering respite care and connecting families with support services can help alleviate some of the stress and challenges associated with caregiving. Engaging in open communication and fostering a supportive environment can improve the overall well-being of both patients and their caregivers.

Conclusion

In summary, managing the cognitive and motor symptoms of Huntington's Disease involves a comprehensive approach that combines pharmacological treatments with non-pharmacological interventions. Effective management requires addressing motor symptoms through medications and therapies, supporting cognitive function with rehabilitation and mental health support and addressing psychiatric symptoms with both pharmacological and psychological

***Address for Correspondence:** Wang Cui, Department of Neurology, The Affiliated Hospital of Chifeng University, Chifeng, China, E-mail: wangcuiwc45@gmail.com*

***Copyright:** © 2024 Cui W. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.*

Received: 01 August, 2024, Manuscript No. jcnn-24-145893; **Editor Assigned:** 03 August, 2024, Pre QC No. P-145893; **Reviewed:** 17 August, 2024, QC No. Q-145893; **Revised:** 22 August, 2024, Manuscript No. R-145893; **Published:** 29 August, 2024, DOI: 10.37421/2684-6012.2024.7.246

strategies. By adopting a holistic approach tailored to individual needs, it is possible to improve the quality of life for individuals with HD and their families, offering hope and support as they navigate the complexities of this challenging condition.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Rasheed, Nora O. Abdel and Weam W. Ibrahim. "Telmisartan neuroprotective effects in 3-nitropropionic acid Huntington's disease model in rats: Cross talk between PPAR-γ and PI3K/Akt/GSK-3β pathway." *Life Sci* 297 (2022): 120480.
2. Afzal, Muhammad, Nadeem Sayyed, Khalid Saad Alharbi and Sami I. Alzarea, et al. "Anti-Huntington's Effect of Rosiridin *via* Oxidative Stress/AchE Inhibition and Modulation of Succinate Dehydrogenase, Nitrite, and BDNF Levels against 3-Nitropropionic Acid in Rodents." *Biomolecules* 12 (2022): 1023.
3. Ahmadi, Houssein, Mahdi Eskandarian Boroujeni, Yousef Sadeghi and Mohammad Amin Abdollahifar, et al. "Sertoli cells avert neuroinflammation-induced cell death and improve motor function and striatal atrophy in rat model of Huntington disease." *J Mol Neurosci* 65 (2018): 17-27.
4. Albekairi, Thamer H., Arzoo Kamra, Sudeep Bhardwaj and Sidharth Mehan, et al. "Beta-boswellic acid reverses 3-nitropropionic acid-induced molecular, mitochondrial, and histopathological defects in experimental rat model of Huntington's disease." *Biomedicines* 10 (2022): 2866.
5. Alshehri, Sultan, Fahad A. Al-Abbasi, Mohammed M. Ghoneim and Syed Sarim Imam, et al. "Anti-Huntington's effect of butin in 3-nitropropionic acid-treated rats: Possible mechanism of action." *Neurotox Res* 40 (2022): 66-77.

How to cite this article: Cui, Wang. "Managing Cognitive and Motor Symptoms of Huntington's disease." *J Clin Neurol Neurosurg* 7 (2024): 246.